312 related articles for article (PubMed ID: 25658463)
1. WIP1 phosphatase as a potential therapeutic target in neuroblastoma.
Richter M; Dayaram T; Gilmartin AG; Ganji G; Pemmasani SK; Van Der Key H; Shohet JM; Donehower LA; Kumar R
PLoS One; 2015; 10(2):e0115635. PubMed ID: 25658463
[TBL] [Abstract][Full Text] [Related]
2. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
Esfandiari A; Hawthorne TA; Nakjang S; Lunec J
Mol Cancer Ther; 2016 Mar; 15(3):379-91. PubMed ID: 26832796
[TBL] [Abstract][Full Text] [Related]
3. Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis.
Chen Z; Wang L; Yao D; Yang T; Cao WM; Dou J; Pang JC; Guan S; Zhang H; Yu Y; Zhao Y; Wang Y; Xu X; Shi Y; Patel R; Zhang H; Vasudevan SA; Liu S; Yang J; Nuchtern JG
Sci Rep; 2016 Dec; 6():38011. PubMed ID: 27991505
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.
Pechackova S; Burdova K; Benada J; Kleiblova P; Jenikova G; Macurek L
Oncotarget; 2016 Mar; 7(12):14458-75. PubMed ID: 26883108
[TBL] [Abstract][Full Text] [Related]
5. The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma.
Kojima K; Maeda A; Yoshimura M; Nishida Y; Kimura S
Oncotarget; 2016 Oct; 7(43):69625-69637. PubMed ID: 27626308
[TBL] [Abstract][Full Text] [Related]
6. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
Wu CE; Esfandiari A; Ho YH; Wang N; Mahdi AK; Aptullahoglu E; Lovat P; Lunec J
Br J Cancer; 2018 Feb; 118(4):495-508. PubMed ID: 29235570
[TBL] [Abstract][Full Text] [Related]
7. Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D.
Castellino RC; De Bortoli M; Lu X; Moon SH; Nguyen TA; Shepard MA; Rao PH; Donehower LA; Kim JY
J Neurooncol; 2008 Feb; 86(3):245-56. PubMed ID: 17932621
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase.
Yoda A; Toyoshima K; Watanabe Y; Onishi N; Hazaka Y; Tsukuda Y; Tsukada J; Kondo T; Tanaka Y; Minami Y
J Biol Chem; 2008 Jul; 283(27):18969-79. PubMed ID: 18482988
[TBL] [Abstract][Full Text] [Related]
9. Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction.
Gilmartin AG; Faitg TH; Richter M; Groy A; Seefeld MA; Darcy MG; Peng X; Federowicz K; Yang J; Zhang SY; Minthorn E; Jaworski JP; Schaber M; Martens S; McNulty DE; Sinnamon RH; Zhang H; Kirkpatrick RB; Nevins N; Cui G; Pietrak B; Diaz E; Jones A; Brandt M; Schwartz B; Heerding DA; Kumar R
Nat Chem Biol; 2014 Mar; 10(3):181-7. PubMed ID: 24390428
[TBL] [Abstract][Full Text] [Related]
10. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.
Sriraman A; Radovanovic M; Wienken M; Najafova Z; Li Y; Dobbelstein M
Oncotarget; 2016 May; 7(22):31623-38. PubMed ID: 27183917
[TBL] [Abstract][Full Text] [Related]
11. p53-Independent expression of wild-type p53-induced phosphatase 1 (Wip1) in methylmethane sulfonate-treated cancer cell lines and human tumors.
Park JY; Song JY; Kim HM; Han HS; Seol HS; Jang SJ; Choi J
Int J Biochem Cell Biol; 2012 Jun; 44(6):896-904. PubMed ID: 22405851
[TBL] [Abstract][Full Text] [Related]
12. Clinical Significance of the Wild Type p53-Induced Phosphatase 1 Expression in Invasive Breast Cancer.
Inoue Y; Yamashita N; Kitao H; Tanaka K; Saeki H; Oki E; Oda Y; Tokunaga E; Maehara Y
Clin Breast Cancer; 2018 Aug; 18(4):e643-e650. PubMed ID: 29275106
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers.
Yu E; Ahn YS; Jang SJ; Kim MJ; Yoon HS; Gong G; Choi J
Breast Cancer Res Treat; 2007 Mar; 101(3):269-78. PubMed ID: 16897432
[TBL] [Abstract][Full Text] [Related]
14. DNA damage-induced regulatory interplay between DAXX, p53, ATM kinase and Wip1 phosphatase.
Brazina J; Svadlenka J; Macurek L; Andera L; Hodny Z; Bartek J; Hanzlikova H
Cell Cycle; 2015; 14(3):375-87. PubMed ID: 25659035
[TBL] [Abstract][Full Text] [Related]
15. The estrogen receptor alpha pathway induces oncogenic Wip1 phosphatase gene expression.
Han HS; Yu E; Song JY; Park JY; Jang SJ; Choi J
Mol Cancer Res; 2009 May; 7(5):713-23. PubMed ID: 19435816
[TBL] [Abstract][Full Text] [Related]
16. Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma.
Fuku T; Semba S; Yutori H; Yokozaki H
Pathol Int; 2007 Sep; 57(9):566-71. PubMed ID: 17685927
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase.
Fujimoto H; Onishi N; Kato N; Takekawa M; Xu XZ; Kosugi A; Kondo T; Imamura M; Oishi I; Yoda A; Minami Y
Cell Death Differ; 2006 Jul; 13(7):1170-80. PubMed ID: 16311512
[TBL] [Abstract][Full Text] [Related]
18. WIP1 phosphatase at the crossroads of cancer and aging.
Le Guezennec X; Bulavin DV
Trends Biochem Sci; 2010 Feb; 35(2):109-14. PubMed ID: 19879149
[TBL] [Abstract][Full Text] [Related]
19. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways.
Lu X; Nguyen TA; Moon SH; Darlington Y; Sommer M; Donehower LA
Cancer Metastasis Rev; 2008 Jun; 27(2):123-35. PubMed ID: 18265945
[TBL] [Abstract][Full Text] [Related]
20. Wild-type p53-induced phosphatase 1 (Wip1) forestalls cellular premature senescence at physiological oxygen levels by regulating DNA damage response signaling during DNA replication.
Sakai H; Fujigaki H; Mazur SJ; Appella E
Cell Cycle; 2014; 13(6):1015-29. PubMed ID: 24552809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
